adlainortye.com (ANL) Long-Term Debt to Capital Ratio

Adlai Nortye Limited - graphic logo of issuer ANL

The planned capital reduction of Adlai Nortye Ltd. (ANL) may be cause for concern, however, the long-term debt-to-equity ratio on the GURU.Markets terminal linear chart shows that the value has stabilized at 0.04. This confirms the bet on buparlisib to capture the oncology market. Adlai Nortye Ltd. revenues will be based on insurance payouts for innovative head and neck cancer therapy.

Long-Term Debt to Capital: Adlai Nortye Ltd (ANL) for 02/21/2024 - 11/01/2026
Flagship merchandise of Adlai Nortye Ltd.

This ratio measures the proportion of long-term liabilities relative to equity, determining the business's degree of dependence on external financing. The metric's trend allows for an assessment of the company's resilience to credit risks and the efficiency of its financial leverage. By analyzing the ratio of long-term debt to equity, an investor can track the evolution of the liability structure. A decrease in this indicator minimizes default risk. Stable borrowing supports the development of the global oncology pipeline of Adlai Nortye (ANL) across various jurisdictions.

Competing companies

Long-Term Debt to Capital BeiGene Ltd.|Long-Term Debt to Equity Halozyme Inc. (HALO)|Revolution Medicines Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital AAPG (Ascentage Pharma Group)|CGON - Long-Term Debt to Equity Ratio|UroGen Pharma - Long-Term Debt to Capital|Long-Term Liabilities to Capital Bicara Therapeutics Inc|Personalis Corp (PSNL) - Long-Term Debt to Equity|Erasca Oncology - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio DCTH|YMAB: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital AURA|Long-Term Debt to Equity Ratio candeltx.com CADL|Accuray Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital SELLAS Life Sciences Group, Inc. SLS|ACTU - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient CTOR (citiusonc.com)|HURA: Long-Term Debt to Capital|Long-Term Liabilities to Capital Protara Therapeutics Inc (TARA)|FATE (Fate Therapeutics Corp) - Long-Term Debt to Capital|Long-Term Debt to Capital Aadi Bio|Long-Term Debt to Capital TCRX|championsoncology.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Equity XBiotech XBIT|CEL-SCI Corp. - Long-Term Debt to Equity|OS Therapies Inc - Long-Term Debt to Capital|RADX - Long-Term Debt to Capital|ARTV: Long-Term Debt to Capital|VERU - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio TPST|XLO: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Renovaro Inc. (RENB)|muraloncology.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Equity Kairos Pharma KAPA|OnKure Therapeutics, Inc. (OKUR) - Long-Term Liabilities to Capital|GDTC - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient CRIS (Curis, Inc.)|APLM (apollomicsinc.com) - Long-Term Debt to Equity Ratio|THAR: Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Ratio ADVB|Long-Term Liabilities to Capital genprex.com GNPX|Long-Term Debt to Capital CLDI|SBFM - Long-Term Liabilities to Capital|Xenetic Biosciences, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient SLRX|PPBT - Long-Term Debt to Equity|AONC: Long-Term Debt to Equity|BGNE (BeiGene) - Long-Term Debt to Equity Ratio|CKPT: Long-Term Loans to Capital Ratio|ELEV (Elevation Oncology, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital Ratio ICAD (iCAD Corp)|Long-Term Debt to Equity Ratio IKNA (Ikena Oncology, Inc.)|Ratio of Long-Term Indebtedness to Capital notablelabs.com|Long-Term Debt to Capital VIRX (Viracta Therapeutics, Inc.)|Long-Term Debt to Capital MorphoSys Inc MOR|NAYA - Long-Term Debt to Equity|AAPGV (Ascentage) - Long-Term Debt to Capital Ratio